MS-PEKOS
We could not find results for this trial
I know where the results areWhat it found
We found no results in the registry or in papers.
This trial finished 13 months ago. We found no results in the registry or in any paper that cites it.
What it measured
Main measures
Proportion of patients reported local injection-related reaction post first injection
Day 1-7 post first injection, at the time of survey completion
Pain
Other measures (1)
Proportion of patients in a 5-Likert scale for satisfaction on injection-related experience (post first injection)
Day 1-7 post first injection, at the time of survey completion
Quality of life (reported by participants)
Who could take part
MS (type not specified) · 18 to 99
Inclusion Criteria: 1. Ability to use a mobile device or computer with broadband internet access (or data streaming available) 2. Ability to read, understand, and respond in English 3. Adult aged 18 years of age or over at the time of the survey 4. Self-confirmed diagnosis of MS 5. Prescribed either OMB or OCR SC and received their first injection (Day 0) and completed the study survey between Day 1 and Day 7 Exclusion Criteria: 1. Participated in an OMB or OCR randomized clinical trial 2. Previously treated with OMB or OCR SC 3. Cognitive impairment that impacts the patient's ability to participate in a survey study
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The study aimed to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation.
Loading reviews and guidelines…
History
Started
Nov 2024
Main results due
Sept 2025
Finished
Sept 2025
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error